Primary Sjögren's Syndrome Clinical Trials

54 clinical trials for Primary Sjögren's Syndrome across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity — RECRUITING · PHASE2
• Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity — RECRUITING
• A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF IMVT- 1402 IN ADULT PARTICIPANTS WITH PRIMARY SJOGREN’S DISEASE WITH MODERATE TO SEVERE SYSTEMIC DISEASE ACTIVITY — RECRUITING · PHASE2
• Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome — RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED MULTICENTER TRIAL WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD PH20 SUBCUTANEOUS ADMINISTERED BY PREFILLED SYRINGE IN ADULT PATIENTS WITH PRIMARY SJÖGREN¿S DISEASE — RECRUITING · PHASE3
• New Clinical End-points in Patients With Primary Sjögren's Syndrome — RECRUITING · PHASE2
• The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome — RECRUITING · PHASE4
• The ASSESS National Multi-center Prospective Cohort — RECRUITING
• Diagnostic Suspicion of Primitive Syndrome Sjögren's : Brest Cohort — RECRUITING
• A two part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-α Monoclonal Antibody (GSK2618960) in the Treatment of Primary Sjögren’s Syndrome. — TERMINATED · PHASE2
• Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173 — COMPLETED · PHASE2
• A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases — NOT_YET_RECRUITING · PHASE1
• A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome — NOT_YET_RECRUITING · PHASE2
• CM336 for Active Sjogren's Syndrome Study — NOT_YET_RECRUITING · PHASE1
• A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Efficacy of Tocilizumab in Primary Sjögren's Syndrome. — COMPLETED · PHASE2
• A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome — COMPLETED · PHASE3
• Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome — COMPLETED · PHASE1
• A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome — NOT_YET_RECRUITING · NA
• A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) — COMPLETED · PHASE2
• Current Therapy in Primary Sjogren's Syndrome — COMPLETED · NA
• NECESSITY – « New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients » — TERMINATED · PHASE2
• Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome — NOT_YET_RECRUITING · PHASE2
• Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome; RepurpSS-II study — OTHER · PHASE2
• Acupuncture Combined With Hydroxychloroquine — COMPLETED · NA
• Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients — COMPLETED · PHASE2
• Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome — WITHDRAWN · PHASE2
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis — COMPLETED · PHASE2
• BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome — TERMINATED · PHASE1
• Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome — OTHER · PHASE2
• BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome — WITHDRAWN · PHASE2
• The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory — OTHER
• PD of VAY736 in Patients With Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire — OTHER
• A Study of INCB050465 in Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD — OTHER · NA
• Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome — COMPLETED · PHASE2
• UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome — TERMINATED · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND THERAPEUTIC EFFICACY OF SAR441344 IN ADULT PATIENTS WITH PRIMARY SJOGREN'S SYNDROME (PSJS) — COMPLETED
• Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease — OTHER
• A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome — TERMINATED · PHASE2
• Primary Sjögren Syndrome — COMPLETED
• A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome — WITHDRAWN · PHASE1
• Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome — COMPLETED · PHASE2
• Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study — WITHDRAWN · PHASE2

Refine this search